Skip to main content

07.09.2018 | Original Research

Interpretations of the Term “Actionable” when Discussing Genetic Test Results: What you Mean Is Not What I Heard

verfasst von: Michele C. Gornick, Kerry A. Ryan, Aaron M. Scherer, J. Scott Roberts, Raymond G. De Vries, Wendy R. Uhlmann

Erschienen in: Journal of Genetic Counseling

Einloggen, um Zugang zu erhalten

Abstract

In genomic medicine, the familiarity and inexactness of the term “actionable” can lead to multiple interpretations and mistaken beliefs about realistic treatment options. As part of a larger study focusing on public attitudes toward policies for the return of secondary genomic results, we looked at how members of the lay public interpret the term “medically actionable” in the context of genetic testing. We also surveyed a convenience sample of oncologists as part of a separate study and asked them to define the term “medically actionable.” After being provided with a definition of the term, 21 out of 60 (35%) layperson respondents wrote an additional action not specified in the provided definition (12 mentioned “cure” and 9 mentioned environment or behavioral change) and 17 (28%) indicated “something can be done” with no action specified. In contrast, 52 surveyed oncologists did not mention environment, behavioral change, or cure. Based on our findings, we propose that rather than using the term “actionable” alone, providers should also say “what they mean” to reduce miscommunication and confusion that could negatively impact medical decision-making. Lastly, to guide clinicians during patient-provider discussion about genetic test results, we provide examples of phrasing to facilitate clearer communication and understanding of the term “actionable.”
Anhänge
Nur mit Berechtigung zugänglich
Literatur
Zurück zum Zitat American College of Medical Genetics and Genomics. (2013). Incidental findings in clinical genomics: a clarification. Genetics in Medicine, 15(8), 664–666.CrossRef American College of Medical Genetics and Genomics. (2013). Incidental findings in clinical genomics: a clarification. Genetics in Medicine, 15(8), 664–666.CrossRef
Zurück zum Zitat Ananda, G., Mockus, S., Lundquist, M., Spotlow, V., Simons, A., Mitchell, T., & Srivastava, A. (2015). Development and validation of the JAX Cancer Treatment Profile™ for detection of clinically actionable mutations in solid tumors. Experimental and Molecular Pathology, 98(1), 106–112.CrossRefPubMedPubMedCentral Ananda, G., Mockus, S., Lundquist, M., Spotlow, V., Simons, A., Mitchell, T., & Srivastava, A. (2015). Development and validation of the JAX Cancer Treatment Profile™ for detection of clinically actionable mutations in solid tumors. Experimental and Molecular Pathology, 98(1), 106–112.CrossRefPubMedPubMedCentral
Zurück zum Zitat Astor, J. (2011). Saying what you mean, meaning what you say: language, interaction and interpretation. Journal of Analytical Psychology, 56(2), 203–216.CrossRefPubMed Astor, J. (2011). Saying what you mean, meaning what you say: language, interaction and interpretation. Journal of Analytical Psychology, 56(2), 203–216.CrossRefPubMed
Zurück zum Zitat Berg, J. S., Amendola, L. M., Eng, C., Van Allen, E., Gray, S. W., Wagle, N., & Hisama, F. M. (2013). Processes and preliminary outputs for identification of actionable genes as incidental findings in genomic sequence data in the clinical sequencing exploratory research consortium. Genetics in Medicine, 15(11), 860–867.CrossRefPubMedPubMedCentral Berg, J. S., Amendola, L. M., Eng, C., Van Allen, E., Gray, S. W., Wagle, N., & Hisama, F. M. (2013). Processes and preliminary outputs for identification of actionable genes as incidental findings in genomic sequence data in the clinical sequencing exploratory research consortium. Genetics in Medicine, 15(11), 860–867.CrossRefPubMedPubMedCentral
Zurück zum Zitat Berkman, N. D., Sheridan, S. L., Donahue, K. E., Halpern, D. J., Viera, A., Crotty, K., & Harden, E. (2011). Health literacy interventions and outcomes: an updated systematic review. Evidence report/technology assessment, 199, 1–941. Berkman, N. D., Sheridan, S. L., Donahue, K. E., Halpern, D. J., Viera, A., Crotty, K., & Harden, E. (2011). Health literacy interventions and outcomes: an updated systematic review. Evidence report/technology assessment, 199, 1–941.
Zurück zum Zitat Bieg-Bourne, C. C., Millis, S. Z., Piccioni, D. E., Fanta, P. T., Goldberg, M. E., Chmielecki, J., & Kurzrock, R. (2017). Next-generation sequencing in the clinical setting clarifies patient characteristics and potential actionability. Cancer Research, 77(22), 6313–6320.CrossRefPubMed Bieg-Bourne, C. C., Millis, S. Z., Piccioni, D. E., Fanta, P. T., Goldberg, M. E., Chmielecki, J., & Kurzrock, R. (2017). Next-generation sequencing in the clinical setting clarifies patient characteristics and potential actionability. Cancer Research, 77(22), 6313–6320.CrossRefPubMed
Zurück zum Zitat Biesecker, L. G., & Green, R. C. (2014). Diagnostic clinical genome and exome sequencing. New England Journal of Medicine, 370(25), 2418–2425.CrossRefPubMed Biesecker, L. G., & Green, R. C. (2014). Diagnostic clinical genome and exome sequencing. New England Journal of Medicine, 370(25), 2418–2425.CrossRefPubMed
Zurück zum Zitat Butler, T. M., Johnson-Camacho, K., Peto, M., Wang, N. J., Macey, T. A., Korkola, J. E., & Spellman, P. T. (2015). Exome sequencing of cell-free DNA from metastatic cancer patients identifies clinically actionable mutations distinct from primary disease. PLoS One, 10(8), e0136407.CrossRefPubMedPubMedCentral Butler, T. M., Johnson-Camacho, K., Peto, M., Wang, N. J., Macey, T. A., Korkola, J. E., & Spellman, P. T. (2015). Exome sequencing of cell-free DNA from metastatic cancer patients identifies clinically actionable mutations distinct from primary disease. PLoS One, 10(8), e0136407.CrossRefPubMedPubMedCentral
Zurück zum Zitat Carr, T. H., McEwen, R., Dougherty, B., Johnson, J. H., Dry, J. R., Lai, Z., & Cruzalegui, F. (2016). Defining actionable mutations for oncology therapeutic development. Nature Reviews Cancer, 16(5), 319–329.CrossRefPubMed Carr, T. H., McEwen, R., Dougherty, B., Johnson, J. H., Dry, J. R., Lai, Z., & Cruzalegui, F. (2016). Defining actionable mutations for oncology therapeutic development. Nature Reviews Cancer, 16(5), 319–329.CrossRefPubMed
Zurück zum Zitat Cimino, J. J. (1993). Saying what you mean and meaning what you say: coupling biomedical terminology and knowledge. Academic Medicine, 68(4), 257–260.CrossRefPubMed Cimino, J. J. (1993). Saying what you mean and meaning what you say: coupling biomedical terminology and knowledge. Academic Medicine, 68(4), 257–260.CrossRefPubMed
Zurück zum Zitat Clayman, M. L., Bylund, C. L., Chewning, B., & Makoul, G. (2016). The impact of patient participation in health decisions within medical encounters: a systematic review. Medical Decision Making, 36(4), 427–452.CrossRefPubMed Clayman, M. L., Bylund, C. L., Chewning, B., & Makoul, G. (2016). The impact of patient participation in health decisions within medical encounters: a systematic review. Medical Decision Making, 36(4), 427–452.CrossRefPubMed
Zurück zum Zitat Damodaran, S., Miya, J., Kautto, E., Zhu, E., Samorodnitsky, E., Datta, J., & Roychowdhury, S. (2015). Cancer driver log (CanDL): catalog of potentially actionable cancer mutations. The Journal of Molecular Diagnostics, 17(5), 554–559.CrossRefPubMed Damodaran, S., Miya, J., Kautto, E., Zhu, E., Samorodnitsky, E., Datta, J., & Roychowdhury, S. (2015). Cancer driver log (CanDL): catalog of potentially actionable cancer mutations. The Journal of Molecular Diagnostics, 17(5), 554–559.CrossRefPubMed
Zurück zum Zitat Desmond, A., Kurian, A. W., Gabree, M., Mills, M. A., Anderson, M. J., Kobayashi, Y., & Tung, N. (2015). Clinical actionability of multigene panel testing for hereditary breast and ovarian cancer risk assessment. JAMA Oncology, 1(7), 943–951.CrossRefPubMed Desmond, A., Kurian, A. W., Gabree, M., Mills, M. A., Anderson, M. J., Kobayashi, Y., & Tung, N. (2015). Clinical actionability of multigene panel testing for hereditary breast and ovarian cancer risk assessment. JAMA Oncology, 1(7), 943–951.CrossRefPubMed
Zurück zum Zitat Douglas, M. P., Ladabaum, U., Pletcher, M. J., Marshall, D. A., & Phillips, K. A. (2016). Economic evidence on identifying clinically actionable findings with whole-genome sequencing: a scoping review. Genetics in Medicine, 18(2), 111–116.CrossRefPubMed Douglas, M. P., Ladabaum, U., Pletcher, M. J., Marshall, D. A., & Phillips, K. A. (2016). Economic evidence on identifying clinically actionable findings with whole-genome sequencing: a scoping review. Genetics in Medicine, 18(2), 111–116.CrossRefPubMed
Zurück zum Zitat Fagerlin, A., Zikmund-Fisher, B. J., & Ubel, P. A. (2011). Helping patients decide: ten steps to better risk communication. Journal of the National Cancer Institute, 103(19), 1436–1443.CrossRefPubMedPubMedCentral Fagerlin, A., Zikmund-Fisher, B. J., & Ubel, P. A. (2011). Helping patients decide: ten steps to better risk communication. Journal of the National Cancer Institute, 103(19), 1436–1443.CrossRefPubMedPubMedCentral
Zurück zum Zitat Fantry, A. (2016). A piece of mind. Say what you mean, mean what you say. Journal of the American Medical Association, 315(13), 1337–1338.CrossRefPubMed Fantry, A. (2016). A piece of mind. Say what you mean, mean what you say. Journal of the American Medical Association, 315(13), 1337–1338.CrossRefPubMed
Zurück zum Zitat Ferrarotto, R., Heymach, J. V., & Glisson, B. S. (2016). MYB-fusions and other potential actionable targets in adenoid cystic carcinoma. Current Opinion in Oncology, 28(3), 195–200.CrossRefPubMed Ferrarotto, R., Heymach, J. V., & Glisson, B. S. (2016). MYB-fusions and other potential actionable targets in adenoid cystic carcinoma. Current Opinion in Oncology, 28(3), 195–200.CrossRefPubMed
Zurück zum Zitat Gomes, C. F. A., & Brainerd, C. J. (2012). Dual processes in the development of reasoning: The memory side of the story. In J. Gauffroy & P. Barrouillet (Eds.), The development of thinking and reasoning. New York: Psychology Press. Gomes, C. F. A., & Brainerd, C. J. (2012). Dual processes in the development of reasoning: The memory side of the story. In J. Gauffroy & P. Barrouillet (Eds.), The development of thinking and reasoning. New York: Psychology Press.
Zurück zum Zitat Gornick, M. C., Scherer, A. M., Sutton, E. J., Ryan, K. A., Exe, N. L., Li, M., & De Vries, R. G. (2017). Effect of public deliberation on attitudes toward return of secondary results in genomic sequencing. Journal of Genetic Counseling, 26(1), 122–132.CrossRefPubMed Gornick, M. C., Scherer, A. M., Sutton, E. J., Ryan, K. A., Exe, N. L., Li, M., & De Vries, R. G. (2017). Effect of public deliberation on attitudes toward return of secondary results in genomic sequencing. Journal of Genetic Counseling, 26(1), 122–132.CrossRefPubMed
Zurück zum Zitat Green, R. C., Berg, J. S., Berry, G. T., Biesecker, L. G., Dimmock, D. P., Evans, J. P., & Korf, B. R. (2012). Exploring concordance and discordance for return of incidental findings from clinical sequencing. Genetics in Medicine, 14(4), 405–410.CrossRefPubMedPubMedCentral Green, R. C., Berg, J. S., Berry, G. T., Biesecker, L. G., Dimmock, D. P., Evans, J. P., & Korf, B. R. (2012). Exploring concordance and discordance for return of incidental findings from clinical sequencing. Genetics in Medicine, 14(4), 405–410.CrossRefPubMedPubMedCentral
Zurück zum Zitat Green, R. C., Berg, J. S., Grody, W. W., Kalia, S. S., Korf, B. R., Martin, C. L., & Ormond, K. E. (2013). ACMG recommendations for reporting of incidental findings in clinical exome and genome sequencing. Genetics in Medicine, 15(7), 565–574.CrossRefPubMedPubMedCentral Green, R. C., Berg, J. S., Grody, W. W., Kalia, S. S., Korf, B. R., Martin, C. L., & Ormond, K. E. (2013). ACMG recommendations for reporting of incidental findings in clinical exome and genome sequencing. Genetics in Medicine, 15(7), 565–574.CrossRefPubMedPubMedCentral
Zurück zum Zitat Green, R. C., Goddard, K. A., Jarvik, G. P., Amendola, L. M., Appelbaum, P. S., Berg, J. S., & Blout, C. L. (2016). Clinical sequencing exploratory research consortium: accelerating evidence-based practice of genomic medicine. The American Journal of Human Genetics, 98(6), 1051–1066.CrossRefPubMed Green, R. C., Goddard, K. A., Jarvik, G. P., Amendola, L. M., Appelbaum, P. S., Berg, J. S., & Blout, C. L. (2016). Clinical sequencing exploratory research consortium: accelerating evidence-based practice of genomic medicine. The American Journal of Human Genetics, 98(6), 1051–1066.CrossRefPubMed
Zurück zum Zitat Hawley, S. T., Zikmund-Fisher, B., Ubel, P., Jancovic, A., Lucas, T., & Fagerlin, A. (2008). The impact of the format of graphical presentation on health-related knowledge and treatment choices. Patient Education and Counseling, 73(3), 448–455.CrossRefPubMed Hawley, S. T., Zikmund-Fisher, B., Ubel, P., Jancovic, A., Lucas, T., & Fagerlin, A. (2008). The impact of the format of graphical presentation on health-related knowledge and treatment choices. Patient Education and Counseling, 73(3), 448–455.CrossRefPubMed
Zurück zum Zitat Kalia, S. S., Adelman, K., Bale, S. J., Chung, W. K., Eng, C., Evans, J. P., & Miller, D. T. (2017). Recommendations for reporting of secondary findings in clinical exome and genome sequencing, 2016 update (ACMG SF v2. 0): a policy statement of the American College of Medical Genetics and Genomics. Genetics in Medicine, 19(2), 249–255.CrossRefPubMed Kalia, S. S., Adelman, K., Bale, S. J., Chung, W. K., Eng, C., Evans, J. P., & Miller, D. T. (2017). Recommendations for reporting of secondary findings in clinical exome and genome sequencing, 2016 update (ACMG SF v2. 0): a policy statement of the American College of Medical Genetics and Genomics. Genetics in Medicine, 19(2), 249–255.CrossRefPubMed
Zurück zum Zitat Kraft, S. A., Cho, M. K., Gillespie, K., Halley, M., Varsava, N., Ormond, K. E., & Soo-Jin Lee, S. (2018). Beyond consent: building trusting relationships with diverse populations in precision medicine research. The American Journal of Bioethics, 18(4), 3–20.CrossRefPubMed Kraft, S. A., Cho, M. K., Gillespie, K., Halley, M., Varsava, N., Ormond, K. E., & Soo-Jin Lee, S. (2018). Beyond consent: building trusting relationships with diverse populations in precision medicine research. The American Journal of Bioethics, 18(4), 3–20.CrossRefPubMed
Zurück zum Zitat Lafata, J. E., Shay, L. A., & Winship, J. M. (2017). Understanding the influences and impact of patient-clinician communication in cancer care. Health Expectations, 20(6), 1385–1392.CrossRefPubMedPubMedCentral Lafata, J. E., Shay, L. A., & Winship, J. M. (2017). Understanding the influences and impact of patient-clinician communication in cancer care. Health Expectations, 20(6), 1385–1392.CrossRefPubMedPubMedCentral
Zurück zum Zitat Manolio, T. A., Chisholm, R. L., Ozenberger, B., Roden, D. M., Williams, M. S., Wilson, R., & Eng, C. (2013). Implementing genomic medicine in the clinic: the future is here. Genetics in Medicine, 15(4), 258–267.CrossRefPubMedPubMedCentral Manolio, T. A., Chisholm, R. L., Ozenberger, B., Roden, D. M., Williams, M. S., Wilson, R., & Eng, C. (2013). Implementing genomic medicine in the clinic: the future is here. Genetics in Medicine, 15(4), 258–267.CrossRefPubMedPubMedCentral
Zurück zum Zitat Middha, S., Baheti, S., Hart, S. N., & Kocher, J.-P. A. (2014). From days to hours: reporting clinically actionable variants from whole genome sequencing. PLoS One, 9(2), e86803.CrossRefPubMedPubMedCentral Middha, S., Baheti, S., Hart, S. N., & Kocher, J.-P. A. (2014). From days to hours: reporting clinically actionable variants from whole genome sequencing. PLoS One, 9(2), e86803.CrossRefPubMedPubMedCentral
Zurück zum Zitat Nickerson, R. S. (1999). How we know—and sometimes misjudge—what others know: imputing one’s own knowledge to others. Psychological Bulletin, 125(6), 737–759.CrossRef Nickerson, R. S. (1999). How we know—and sometimes misjudge—what others know: imputing one’s own knowledge to others. Psychological Bulletin, 125(6), 737–759.CrossRef
Zurück zum Zitat O'Daniel, J. M., McLaughlin, H. M., Amendola, L. M., Bale, S. J., Berg, J. S., Bick, D., & Rehm, H. L. (2017). A survey of current practices for genomic sequencing test interpretation and reporting processes in US laboratories. Genetics in Medicine, 19(5), 575–582.CrossRefPubMed O'Daniel, J. M., McLaughlin, H. M., Amendola, L. M., Bale, S. J., Berg, J. S., Bick, D., & Rehm, H. L. (2017). A survey of current practices for genomic sequencing test interpretation and reporting processes in US laboratories. Genetics in Medicine, 19(5), 575–582.CrossRefPubMed
Zurück zum Zitat Pritchard, C. C., Salipante, S. J., Koehler, K., Smith, C., Scroggins, S., Wood, B., & Adey, A. (2014). Validation and implementation of targeted capture and sequencing for the detection of actionable mutation, copy number variation, and gene rearrangement in clinical cancer specimens. The Journal of Molecular Diagnostics, 16(1), 56–67.CrossRefPubMed Pritchard, C. C., Salipante, S. J., Koehler, K., Smith, C., Scroggins, S., Wood, B., & Adey, A. (2014). Validation and implementation of targeted capture and sequencing for the detection of actionable mutation, copy number variation, and gene rearrangement in clinical cancer specimens. The Journal of Molecular Diagnostics, 16(1), 56–67.CrossRefPubMed
Zurück zum Zitat Ramos, E. M., Din-Lovinescu, C., Berg, J. S., Brooks, L. D., Duncanson, A., Dunn, M., & O'Donnell, C. (2014). Characterizing genetic variants for clinical action. American Journal of Medical Genetics Part C: Seminars in Medical Genetics, 166(1), 93–104.CrossRef Ramos, E. M., Din-Lovinescu, C., Berg, J. S., Brooks, L. D., Duncanson, A., Dunn, M., & O'Donnell, C. (2014). Characterizing genetic variants for clinical action. American Journal of Medical Genetics Part C: Seminars in Medical Genetics, 166(1), 93–104.CrossRef
Zurück zum Zitat Reyna, V. F., & Brainerd, C. J. (1995). Fuzzy-trace theory: an interim synthesis. Learning and Individual Differences, 7(1), 1–75.CrossRef Reyna, V. F., & Brainerd, C. J. (1995). Fuzzy-trace theory: an interim synthesis. Learning and Individual Differences, 7(1), 1–75.CrossRef
Zurück zum Zitat Rudd, R. E., Kaphingst, K., Colton, T., Gregoire, J., & Hyde, J. (2004). Rewriting public health information in plain language. Journal of Health Communication, 9(3), 195–206.CrossRefPubMed Rudd, R. E., Kaphingst, K., Colton, T., Gregoire, J., & Hyde, J. (2004). Rewriting public health information in plain language. Journal of Health Communication, 9(3), 195–206.CrossRefPubMed
Zurück zum Zitat Ryan, K. A., De Vries, R. G., Uhlmann, W. R., Roberts, J. S., & Gornick, M. C. (2017). Public’s views toward return of secondary results in genomic sequencing: It’s (almost) all about the choice. Journal of Genetic Counseling, 26(6), 1197–1212.CrossRefPubMed Ryan, K. A., De Vries, R. G., Uhlmann, W. R., Roberts, J. S., & Gornick, M. C. (2017). Public’s views toward return of secondary results in genomic sequencing: It’s (almost) all about the choice. Journal of Genetic Counseling, 26(6), 1197–1212.CrossRefPubMed
Zurück zum Zitat Schwaederle, M., Husain, H., Fanta, P. T., Piccioni, D. E., Kesari, S., Schwab, R. B., & Parker, B. A. (2016). Detection rate of actionable mutations in diverse cancers using a biopsy-free (blood) circulating tumor cell DNA assay. Oncotarget, 7(9), 9707–9717.CrossRefPubMedPubMedCentral Schwaederle, M., Husain, H., Fanta, P. T., Piccioni, D. E., Kesari, S., Schwab, R. B., & Parker, B. A. (2016). Detection rate of actionable mutations in diverse cancers using a biopsy-free (blood) circulating tumor cell DNA assay. Oncotarget, 7(9), 9707–9717.CrossRefPubMedPubMedCentral
Zurück zum Zitat Shay, L. A., & Lafata, J. E. (2014). Understanding patient perceptions of shared decision making. Patient Education and Counseling, 96(3), 295–301.CrossRefPubMedPubMedCentral Shay, L. A., & Lafata, J. E. (2014). Understanding patient perceptions of shared decision making. Patient Education and Counseling, 96(3), 295–301.CrossRefPubMedPubMedCentral
Zurück zum Zitat Shirts, B. H., Salama, J. S., Aronson, S. J., Chung, W. K., Gray, S. W., Hindorff, L. A., & Tarczy-Hornoch, P. Z. (2015). CSER and eMERGE: current and potential state of the display of genetic information in the electronic health record. Journal of the American Medical Informatics Association, 22(6), 1231–1242.PubMedPubMedCentral Shirts, B. H., Salama, J. S., Aronson, S. J., Chung, W. K., Gray, S. W., Hindorff, L. A., & Tarczy-Hornoch, P. Z. (2015). CSER and eMERGE: current and potential state of the display of genetic information in the electronic health record. Journal of the American Medical Informatics Association, 22(6), 1231–1242.PubMedPubMedCentral
Zurück zum Zitat Sukhai, M. A., Craddock, K. J., Thomas, M., Hansen, A. R., Zhang, T., Siu, L., & Kamel-Reid, S. (2016). A classification system for clinical relevance of somatic variants identified in molecular profiling of cancer. Genetics in Medicine, 18(2), 128–136.CrossRefPubMed Sukhai, M. A., Craddock, K. J., Thomas, M., Hansen, A. R., Zhang, T., Siu, L., & Kamel-Reid, S. (2016). A classification system for clinical relevance of somatic variants identified in molecular profiling of cancer. Genetics in Medicine, 18(2), 128–136.CrossRefPubMed
Zurück zum Zitat Tait, A. R., Zikmund-Fisher, B. J., Fagerlin, A., & Voepel-Lewis, T. (2010). Effect of various risk/benefit trade-offs on parents’ understanding of a pediatric research study. Pediatrics, 125(6), e1475–e1482.CrossRefPubMedPubMedCentral Tait, A. R., Zikmund-Fisher, B. J., Fagerlin, A., & Voepel-Lewis, T. (2010). Effect of various risk/benefit trade-offs on parents’ understanding of a pediatric research study. Pediatrics, 125(6), e1475–e1482.CrossRefPubMedPubMedCentral
Zurück zum Zitat Thierry, A., El Messaoudi, S., Mollevi, C., Raoul, J., Guimbaud, R., Pezet, D., & Mathonnet, M. (2017). Clinical utility of circulating DNA analysis for rapid detection of actionable mutations to select metastatic colorectal patients for anti-EGFR treatment. Annals of Oncology, 28(9), 2149–2159.CrossRefPubMed Thierry, A., El Messaoudi, S., Mollevi, C., Raoul, J., Guimbaud, R., Pezet, D., & Mathonnet, M. (2017). Clinical utility of circulating DNA analysis for rapid detection of actionable mutations to select metastatic colorectal patients for anti-EGFR treatment. Annals of Oncology, 28(9), 2149–2159.CrossRefPubMed
Zurück zum Zitat Vandekerkhove, G. R., Todenhöfer, T., Annala, M., Struss, W. J., Wong, A., Beja, K., & Hennenlotter, J. (2017). Circulating tumor DNA reveals clinically-actionable somatic genome of metastatic bladder cancer. Clinical Cancer Research, 23(21), 6487–6497.CrossRefPubMed Vandekerkhove, G. R., Todenhöfer, T., Annala, M., Struss, W. J., Wong, A., Beja, K., & Hennenlotter, J. (2017). Circulating tumor DNA reveals clinically-actionable somatic genome of metastatic bladder cancer. Clinical Cancer Research, 23(21), 6487–6497.CrossRefPubMed
Zurück zum Zitat Vidwans, S. J., Turski, M. L., Janku, F., Garrido-Laguna, I., Munoz, J., Schwab, R., & Kurzrock, R. (2014). A framework for genomic biomarker actionability and its use in clinical decision making. Oncoscience, 1(10), 614–623.CrossRefPubMedPubMedCentral Vidwans, S. J., Turski, M. L., Janku, F., Garrido-Laguna, I., Munoz, J., Schwab, R., & Kurzrock, R. (2014). A framework for genomic biomarker actionability and its use in clinical decision making. Oncoscience, 1(10), 614–623.CrossRefPubMedPubMedCentral
Zurück zum Zitat Wong, S., Fellowes, A., Doig, K., Ellul, J., Bosma, T., Irwin, D., & Chan, K. (2015). Assessing the clinical value of targeted massively parallel sequencing in a longitudinal, prospective population-based study of cancer patients. British Journal of Cancer, 112(8), 1411–1420.CrossRefPubMedPubMedCentral Wong, S., Fellowes, A., Doig, K., Ellul, J., Bosma, T., Irwin, D., & Chan, K. (2015). Assessing the clinical value of targeted massively parallel sequencing in a longitudinal, prospective population-based study of cancer patients. British Journal of Cancer, 112(8), 1411–1420.CrossRefPubMedPubMedCentral
Zurück zum Zitat Wyatt, A. W., Azad, A. A., Volik, S. V., Annala, M., Beja, K., McConeghy, B., & Brahmbhatt, S. (2016). Genomic alterations in cell-free DNA and enzalutamide resistance in castration-resistant prostate cancer. JAMA Oncology, 2(12), 1598–1606.CrossRefPubMedPubMedCentral Wyatt, A. W., Azad, A. A., Volik, S. V., Annala, M., Beja, K., McConeghy, B., & Brahmbhatt, S. (2016). Genomic alterations in cell-free DNA and enzalutamide resistance in castration-resistant prostate cancer. JAMA Oncology, 2(12), 1598–1606.CrossRefPubMedPubMedCentral
Zurück zum Zitat Yuan, Y., Liu, L., Chen, H., Wang, Y., Xu, Y., Mao, H., & Li, L. (2016). Comprehensive characterization of molecular differences in cancer between male and female patients. Cancer Cell, 29(5), 711–722.CrossRefPubMedPubMedCentral Yuan, Y., Liu, L., Chen, H., Wang, Y., Xu, Y., Mao, H., & Li, L. (2016). Comprehensive characterization of molecular differences in cancer between male and female patients. Cancer Cell, 29(5), 711–722.CrossRefPubMedPubMedCentral
Zurück zum Zitat Zikmund-Fisher, B. J. (2017). When “actionable” genomic sequencing results cannot be acted upon. JAMA Oncology, 3(7), 891–892.CrossRefPubMed Zikmund-Fisher, B. J. (2017). When “actionable” genomic sequencing results cannot be acted upon. JAMA Oncology, 3(7), 891–892.CrossRefPubMed
Metadaten
Titel
Interpretations of the Term “Actionable” when Discussing Genetic Test Results: What you Mean Is Not What I Heard
verfasst von
Michele C. Gornick
Kerry A. Ryan
Aaron M. Scherer
J. Scott Roberts
Raymond G. De Vries
Wendy R. Uhlmann
Publikationsdatum
07.09.2018
Verlag
Springer US
Erschienen in
Journal of Genetic Counseling
Print ISSN: 1059-7700
Elektronische ISSN: 1573-3599
DOI
https://doi.org/10.1007/s10897-018-0289-6

Hirsutismus bei PCOS: Laser- und Lichttherapien helfen

26.04.2024 Hirsutismus Nachrichten

Laser- und Lichtbehandlungen können bei Frauen mit polyzystischem Ovarialsyndrom (PCOS) den übermäßigen Haarwuchs verringern und das Wohlbefinden verbessern – bei alleiniger Anwendung oder in Kombination mit Medikamenten.

ICI-Therapie in der Schwangerschaft wird gut toleriert

Müssen sich Schwangere einer Krebstherapie unterziehen, rufen Immuncheckpointinhibitoren offenbar nicht mehr unerwünschte Wirkungen hervor als andere Mittel gegen Krebs.

Weniger postpartale Depressionen nach Esketamin-Einmalgabe

Bislang gibt es kein Medikament zur Prävention von Wochenbettdepressionen. Das Injektionsanästhetikum Esketamin könnte womöglich diese Lücke füllen.

Bei RSV-Impfung vor 60. Lebensjahr über Off-Label-Gebrauch aufklären!

22.04.2024 DGIM 2024 Kongressbericht

Durch die Häufung nach der COVID-19-Pandemie sind Infektionen mit dem Respiratorischen Synzytial-Virus (RSV) in den Fokus gerückt. Fachgesellschaften empfehlen eine Impfung inzwischen nicht nur für Säuglinge und Kleinkinder.

Update Gynäkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert – ganz bequem per eMail.